Literature DB >> 16213184

Protection against Helicobacter pylori infection in the Mongolian gerbil after prophylactic vaccination.

A H T Jeremy1, Y Du, M F Dixon, P A Robinson, J E Crabtree.   

Abstract

Vaccines against Helicobacter pylori could circumvent the problem of increasing antibiotic resistance. They would be particularly useful in developing countries, where re-infection rates are high following standard eradication regimes. The Mongolian gerbil is a good model for H. pylori infection, as the gastric pathology induced by infection is similar to that in humans. The H. pylori-induced inflammatory response in gerbils is considerably greater than in murine models. The aim of this study was to determine if gerbils could be vaccinated against H. pylori. Mongolian gerbils were vaccinated orally with an H. pylori whole cell sonicate preparation and cholera toxin adjuvant. Vaccinated gerbils and controls were challenged with the autologous H. pylori strain 42GX. All infection, and cholera toxin, control gerbils were H. pylori positive 6 weeks post-challenge. By contrast, a significant degree of protection was demonstrated in vaccinated gerbils. Only two of 10 of gerbils were H. pylori positive (P<0.001). Protection was associated with increased serum H. pylori IgG antibodies. Protected gerbils had histologically normal gastric mucosa and, in contrast to mice, no post-immunisation gastritis was evident. In the control groups, the degree of inflammation was variable, with some of the animals having corpus gastritis and corpus mucous metaplasia. The levels of gastric IL-12p40 and IFNgamma transcripts were significantly decreased in vaccinated animals compared to infection and cholera toxin controls (P<0.01). Gastric IL-10 and TGFbeta transcripts were found only at relatively low levels. These results demonstrate that Mongolian gerbils can be successfully vaccinated against H. pylori and protected from H. pylori-induced pathology.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16213184     DOI: 10.1016/j.micinf.2005.06.025

Source DB:  PubMed          Journal:  Microbes Infect        ISSN: 1286-4579            Impact factor:   2.700


  10 in total

1.  Th immune response induced by H pylori vaccine with chitosan as adjuvant and its relation to immune protection.

Authors:  Yong Xie; Nan-Jin Zhou; Yan-Feng Gong; Xiao-Jiang Zhou; Jiang Chen; Si-Juan Hu; Nong-Hua Lu; Xiao-Hua Hou
Journal:  World J Gastroenterol       Date:  2007-03-14       Impact factor: 5.742

Review 2.  Helicobacter pylori persistence: an overview of interactions between H. pylori and host immune defenses.

Authors:  Holly M Scott Algood; Timothy L Cover
Journal:  Clin Microbiol Rev       Date:  2006-10       Impact factor: 26.132

Review 3.  Vaccinating against Helicobacter pylori in the developing world.

Authors:  Shamila Zawahir; Steven J Czinn; John G Nedrud; Thomas G Blanchard
Journal:  Gut Microbes       Date:  2013-11-06

4.  Construction of recombinant attenuated Salmonella typhimurium DNA vaccine expressing H pylori ureB and IL-2.

Authors:  Can Xu; Zhao-Shen Li; Yi-Qi Du; Yan-Fang Gong; Hua Yang; Bo Sun; Jing Jin
Journal:  World J Gastroenterol       Date:  2007-02-14       Impact factor: 5.742

Review 5.  Pathogenesis of Helicobacter pylori infection.

Authors:  Johannes G Kusters; Arnoud H M van Vliet; Ernst J Kuipers
Journal:  Clin Microbiol Rev       Date:  2006-07       Impact factor: 26.132

Review 6.  Exploring alternative treatments for Helicobacter pylori infection.

Authors:  Guadalupe Ayala; Wendy Itzel Escobedo-Hinojosa; Carlos Felipe de la Cruz-Herrera; Irma Romero
Journal:  World J Gastroenterol       Date:  2014-02-14       Impact factor: 5.742

7.  Effects of a Th1- versus a Th2-biased immune response in protection against Helicobacter pylori challenge in mice.

Authors:  Jennifer M Taylor; Melanie E Ziman; Don R Canfield; Michael Vajdy; Jay V Solnick
Journal:  Microb Pathog       Date:  2007-07-05       Impact factor: 3.738

8.  Possible correlates of long-term protection against Helicobacter pylori following systemic or combinations of mucosal and systemic immunizations.

Authors:  Jennifer M Taylor; Melanie E Ziman; Julie Fong; Jay V Solnick; Michael Vajdy
Journal:  Infect Immun       Date:  2007-05-14       Impact factor: 3.441

9.  Leptin, CD4(+) T(reg) and the prospects for vaccination against H. pylori infection.

Authors:  Anna K Walduck; Dorit Becher
Journal:  Front Immunol       Date:  2012-10-15       Impact factor: 7.561

10.  Immunization with the immunodominant Helicobacter suis urease subunit B induces partial protection against H. suis infection in a mouse model.

Authors:  Miet Vermoote; Katleen Van Steendam; Bram Flahou; Annemieke Smet; Frank Pasmans; Pieter Glibert; Richard Ducatelle; Dieter Deforce; Freddy Haesebrouck
Journal:  Vet Res       Date:  2012-10-26       Impact factor: 3.683

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.